Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home

Journal of Autism and Developmental Disorders

Volumn 46, Issue 6, 2016, Pages 1887-1894

  Ruiz, Lisa M ^a   Damron, Mackenzie ^b   Jones, Kyle B ^a   Weedon, Dean ^a   Carbone, Paul S ^a   Bakian, Amanda V ^a   Bilder, Deborah A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Antipsychotics; Autism spectrum disorder; Intellectual disability; Medical home

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; AUTISM; CHILD; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MIDDLE AGED; MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AUTISM SPECTRUM DISORDER; BLOOD; BODY WEIGHT; COMPLICATION; DEVELOPMENTAL DISABILITIES; DRUG EFFECTS; INTELLECTUAL DISABILITY; METABOLISM; PATIENT CARE; PRESCHOOL CHILD; SEX DIFFERENCE; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; AUTISM SPECTRUM DISORDER; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; INTELLECTUAL DISABILITY; LIPIDS; MALE; MEDICAID; MIDDLE AGED; PATIENT-CENTERED CARE; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84955575873     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-016-2712-x     Document Type: Article

References (29)

1. Aman, M. G., Lam, K. L., & Van Bourgondien, M. E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology,15(1), 116–126.
2. Baburaj, R., & El Tahir, M. (2011). Monitoring for metabolic syndrome in people with intellectual disability on antipsychotic medication. Advances in Mental Health and Intellectual Disabilities,5(3), 38–44.
3. Bansal, S., Buring, J., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007). Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Journal of American Medical Association,298(3), 309–316.
4. Barnes, T. P. (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatrica Scandinavica,118(1), 26–33.
5. Bhaumik, S. W. (2008). Body mass index in adults with intellectual disability: Distribution, associations and service implications: A population-based prevalence study. Journal of Intellectual Disability Research,52(4), 287–298.
6. Buck, T. R., Viskochil, J., Farley, M., Coon, H., McMahon, W. M., Morgan, J., & Bilder, D. A. (2014). Psychiatric comorbidity and medication use in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders,44(12), 3063–3071.
7. Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Journal of Clinical Psychiatry, 65(2), 267–272. doi:10.4088/JCP.v65n0219
8. Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., & Perrin, J. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics,130(Suppl 2), S69–S76.
9. Devapriam, J., Anand, A., Raju, L., & Bhaumik, S. (2009). Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs. British Journal of Developmental Disabilities,55(Part 1(108)), 3–13.
10. Eberly, L. E., Stamler, J., & Neaton, J. D. (2003). Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine, 163(1), 1077–1083.
11. Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001). Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research,101(3), 277–288. doi:10.1016/S0165-1781(01)00234-7.
12. Frighi, V., Stephenson, M. T., Morovat, A., Jolley, I. E., Trivella, M., Dudley, C. A., & Goodwin, G. M. (2011). Safety of antipsychotics in people with intellectual disability. The British Journal of Psychiatry: The Journal of Mental Science,199(4), 289–295. doi:10.1192/bjp.bp.110.085670.
13. Ghate, S. I. (2012). Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Mental Health In Family Medicine,9(3), 137–148.
14. Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry,166(3), 345–353.
15. Hsu, C., Ried, L. D., Bengtson, M. A., Garman, P. M., McConkey, J. R., & Rahnavard, F. (2008). Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association: Japha,48(3), 393–400. doi:10.1331/JAPhA.2008.07007.
16. Koch, D. A., & Scott, A. J. (2012). Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: Comparisons for prescriptions administered using algorithms versus usual care. Journal of Psychiatric and Mental Health Nursing,19(5), 389–394. doi:10.1111/j.1365-2850.2011.01781.x.
17. Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine,42(1), 125–147. doi:10.1017/S003329171100105X.
18. Moeller, K. E., Rigler, S. K., Mayorga, A., Nazir, N., & Shireman, T. I. (2011). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research,126(1–3), 117–123. doi:10.1016/j.schres.2010.11.015.
19. Morgan, C. N., Roy, M., & Chance, P. (2003). Psychiatric comorbidity and medication use in autism: A community survey. Psychiatric Bulletin,27(10), 378–381. doi:10.1192/pb.27.10.378.
20. Morrato, E., Nicol, G., Maahs, D., Druss, B., Hartung, D., Valuck, R., & Newcomer, J. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine,164(4), 344–351. doi:10.1001/archpediatrics.2010.48.
21. Mukherjee, S., Schnur, D. B., & Reddy, F. (1989). Family history of type 2 diabetes in schizophrenia patients. Lancet,1, 495.
22. Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007). Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Journal Of American Medical Association,298(3), 299–308.
23. Paton, C. T. (2011). Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. Journal of Intellectual Disability Research,55(7), 665–674.
24. Ryan, M. C., Collins, P., & Thakore, M. B. (2003). Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry,160(2), 284–289.
25. Shi, L., Ascher-Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V., & Winstead, D. (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. doi:10.1186/1471-244X-9-80.
26. Teeluckdharry, S., Sharma, S., O’Rourke, E., Tharian, P., Gondalekar, A., Nainar, F., & Roy, M. (2013). Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. Journal of Intellectual Disabilities,17(3), 223–235. doi:10.1177/1744629513495261.
27. Tsiouris, J., Kim, S., Brown, W., Pettinger, J., & Cohen, I. (2013). Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders,43(3), 719–731.
28. Weedon, D., Carbone, P., Bilder, D., O’Brien, S., & Dorius, J. (2012). Building a person-centered medical home: Lessons from a program for people with developmental disabilities. Journal of Health Care for the Poor and Underserved,23(4), 1600–1608.
29. Wysokiński, A., Kowman, M., & Kłoszewska, I. (2012). The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics—a retrospective medical records review. Psychiatria Danubina,24(3), 314–322.